2-(1-己炔-1-基)-N-甲基-腺苷 | 403842-38-6

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘌呤核苷
• 中文名称: 2-(1-己炔-1-基)-N-甲基-腺苷
• 英文名称: [3H]-HEMADO
• 英文别名: HEMADO；[³H]2-(1-hexynyl)-N⁶-methyladenosine；[³H]2-(1-hexynyl)-N-methyladenosine；2-(hexyn-1-yl)-N⁶-methyladenosine；2-hexyn-1-yl-N⁶-methyladenosine；[3H]-2-(1-hexynyl)-N6-methyladenosine；(2R,3R,4S,5R)-2-[2-hex-1-ynyl-6-(methylamino)purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol
• CAS: 403842-38-6
• 化学式: C₁₇H₂₃N₅O₄
• 分子量: 361.401
• InChiKey: KOCIMZNSNPOGOP-IWCJZZDYSA-N

物化性质

• 溶解度：
  二甲基亚砜：16 毫克/毫升

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  26
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.59
• 拓扑面积：
  126
• 氢给体数：
  4
• 氢受体数：
  8

安全信息

• 危险品标志：
  Xn
• 危险类别码：
  R22
• WGK Germany：
  3
• 安全说明：
  S36

反应信息

• 作为产物：
  描述：

  2',3',5'-三-O-乙酰-6-氯-2-碘嘌呤核苷 在 bis-triphenylphosphine-palladium(II) chloride 、 copper(l) iodide 、 三乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 17.5h， 生成 2-(1-己炔-1-基)-N-甲基-腺苷
  参考文献：
  名称：

  N⁶-Alkyl-2-alkynyl Derivatives of Adenosine as Potent and Selective Agonists at the Human Adenosine A₃ Receptor and a Starting Point for Searching A_2B Ligands

  摘要：

  A series of N-6-alkyl-2-alkynyl derivatives of adenosine (Ado) have been synthesized and evaluated for their affinity at human A(1), A(2A), and A(3) receptors and for their potency at A(2B) adenosine receptor subtypes. The corresponding 2-(1-alkynyl) derivatives of 5'-N-ethylcarboxamidoadenosine (NECA) and Ado are used as reference compounds. Binding studies demonstrated that the activities of 2-alkynylAdos were slightly increased for the adenosine A, receptor and slightly decreased for both A(3) and A(2B) subtypes compared to those of their corresponding NECA derivatives, whereas the A(2A) receptor affinities of the two series of nucleosides were similar. The presence of a methyl group on N-6 of the 2-alkynyladenosines, inducing an increase in affinity at the human A(3) receptor and a decrease at the other subtypes, resulted in an increase in A(3) selectivity. In particular, 2-phenylethynyl-N-6-methylAdo (8b) showed an A(3) affinity in the low nanomolar range (K-i(A(3)) = 3.4 nM), with a A(1)/A(3) and A(2A)/A(3) selectivity of about 500 and 2500, respectively. These findings motivated us to search for the preparation of new selective radioligands for the A(3) subtype; hence, a procedure to introduce a tritiated alkylamino group in these molecules was carried out. As far as the potency at the A(2B) receptor, the type of 2-alkynyl chain and the presence of the ethylcarboxamido group on the sugar seem to be very important; in fact, the (S)-2-phenylhydroxypropynylNECA [(S)-PHPNECA, 1e, EC50(A(2B)) = 0.22 muM] proved to be one of the most potent A(2B) agonist reported so far. On the other hand, the (S)-2-phenylhydroxypropynyl-N-6-ethylAdo (9e, EC50(A(2B)) = 0.73 muM) showed a significantly increase of potency at the A(2B) subtype in comparison with the N-6-methyl, N-6-isopropyl, and the unsubstituted adenosine derivatives, although it resulted in being less potent than (S)PHPNECA (le, EC50(A(2B)) = 0.22 muM). These observations suggest that the introduction of an ethyl group in the N-6-position and an ethylcarboxamido substituent in the 4'-position of (S)2-phenylhydroxypropynyladenosine could lead to a compound endowed with high potency at the A(2B) receptor.

  DOI：

  10.1021/jm0109762

文献信息

• [EN] COMPOUNDS AND METHODS FOR TREATING ADDICTION AND RELATED DISORDERS<br/>[FR] COMPOSÉS ET MÉTHODES DE TRAITEMENT D'UNE DÉPENDANCE ET DE TROUBLES ASSOCIÉS
  申请人：ASTROCYTE PHARMACEUTICALS INC

  公开号：WO2019157317A1

  公开（公告）日：2019-08-15

  The present invention relates to compounds and methods of use thereof for treatment of certain disorders and conditions, for example an addiction or compulsive disorder.

  本发明涉及化合物及其治疗某些疾病和症状的方法，例如成瘾或强迫性障碍。
• Methods, compositions, and kits for the treatment of ophthalmic disorders
  申请人：CombinatoRx, Inc.

  公开号：EP2218442A1

  公开（公告）日：2010-08-18

  The invention features methods, compositions and kits comprising a corticosteroid and a non-steroidal immunophilin-dependent immunosuppressant for treating an ophthalmic disorder in a patient, wherein at least one of said corticosteroid and said non-steroidal immunophilin-dependent immunosuppressant is present at a low concentration, in particular wherein said corticosteroid is prednisolone acetate and said non-steroidal immunophilin-dependent immunosuppressant is cyclosporine A.

  本发明的特征是包含皮质类固醇和非类固醇免疫嗜血素依赖性免疫抑制剂的方法、组合物和试剂盒，用于治疗患者的眼科疾病、其中，所述皮质类固醇和所述非类固醇免疫嗜血素依赖性免疫抑制剂中至少有一种以低浓度存在，特别是所述皮质类固醇为醋酸泼尼松龙，所述非类固醇免疫嗜血素依赖性免疫抑制剂为环孢素 A。
• Compounds and methods for treating neurological and cardiovascular conditions
  申请人：Astrocyte Pharmaceuticals, Inc.

  公开号：US10265338B2

  公开（公告）日：2019-04-23

  The present invention relates to compounds and methods of use thereof for treatment of certain disorders and conditions, for example brain injuries such as stroke or traumatic brain injuries.

  本发明涉及用于治疗某些疾病和病症（例如脑损伤，如中风或脑外伤）的化合物及其使用方法。
• Method of increasing satellite cell proliferation with an HDAC inhibitor
  申请人：PRESIDENT AND FELLOWS OF HARVARD COLLEGE

  公开号：US10660902B2

  公开（公告）日：2020-05-26

  The invention provides methods for inducing, enhancing or increasing satellite cell proliferation, and an assay for screening for a candidate compound for inducing, enhancing or increasing satellite cell proliferation. Also provided are methods for repairing or regenerating a damaged muscle tissue of a subject.

  本发明提供了诱导、增强或增加卫星细胞增殖的方法，以及用于筛选诱导、增强或增加卫星细胞增殖的候选化合物的检测方法。本发明还提供了修复或再生受试者受损肌肉组织的方法。
• Small molecules for mouse satellite cell proliferation
  申请人：President and Fellows of Harvard College

  公开号：US11026952B2

  公开（公告）日：2021-06-08

  The invention provides methods for inducing, enhancing or increasing satellite cell proliferation, and an assay for screening for a candidate compound for inducing, enhancing or increasing satellite cell proliferation. Also provided are methods for repairing or regenerating a damaged muscle tissue of a subject.

  本发明提供了诱导、增强或增加卫星细胞增殖的方法，以及用于筛选诱导、增强或增加卫星细胞增殖的候选化合物的检测方法。本发明还提供了修复或再生受试者受损肌肉组织的方法。